Regeneron Pharmaceuticals Inc. (REGN)

312.56
NASDAQ : Health Technology
Prev Close 315.26
Day Low/High 308.47 / 318.81
52 Wk Low/High 291.69 / 442.00
Avg Volume 824.10K
Exchange NASDAQ
Shares Outstanding 107.73M
Market Cap 34.56B
EPS 22.60
P/E Ratio 14.93
Div & Yield N.A. (N.A)

Latest News

FDA Approves EYLEA® (aflibercept) Injection For Diabetic Retinopathy

FDA Approves EYLEA® (aflibercept) Injection For Diabetic Retinopathy

- EYLEA improves diabetic retinopathy and prevents worsening disease that can lead to blindness

Regeneron Stock Could Fall 13% to 52-Week Lows

Regeneron Stock Could Fall 13% to 52-Week Lows

Regeneron stock is under pressure after missing on earnings and revenue expectations. Are new lows on tap?

Regeneron Declines on First-Quarter Earnings Miss

Regeneron Declines on First-Quarter Earnings Miss

The company misses big on analysts bottom-line expectations.

Regeneron Pharmaceuticals Expected to Earn $5.48 a Share

Regeneron Pharmaceuticals Expected to Earn $5.48 a Share

Regeneron Pharmaceuticals revenue expected to rise 16.8% to $1.8 billion.

Real Money Post-Industrial Average Leaves Major Indices in the Dust

Real Money Post-Industrial Average Leaves Major Indices in the Dust

RMPIA outperformed once gain during April.

Regeneron Announces Upcoming Investor Conference Presentations

Regeneron Announces Upcoming Investor Conference Presentations

TARRYTOWN, N.Y.

How to Invest at Every Age: Cramer's 'Mad Money' Recap (Monday 4/22/19)

How to Invest at Every Age: Cramer's 'Mad Money' Recap (Monday 4/22/19)

Jim Cramer looks at the investment strategies you and your family need to employ throughout your life.

Noteworthy Monday Option Activity: REGN, CARA, RGNX

Noteworthy Monday Option Activity: REGN, CARA, RGNX

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Regeneron Pharmaceuticals, Inc. , where a total of 9,068 contracts have traded so far, representing approximately 906,800 underlying shares.

A Bullish Play on Netflix

A Bullish Play on Netflix

Netflix is bullish, but faces key resistance before it can make a big run higher.

Stalking an Entry in Regeneron Pharmaceuticals

Stalking an Entry in Regeneron Pharmaceuticals

A low-risk countertrend options trade may be worth a look in this name.

Regeneron Pharmaceuticals Becomes #200 Most Shorted S&P 500 Component, Replacing Roper Technologies

Regeneron Pharmaceuticals Becomes #200 Most Shorted S&P 500 Component, Replacing Roper Technologies

The most recent short interest data has been released for the 03/29/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Alnylam And Regeneron Announce Broad Collaboration To Discover, Develop And Commercialize RNAi Therapeutics Focused On Ocular And Central Nervous System (CNS) Diseases

Alnylam And Regeneron Announce Broad Collaboration To Discover, Develop And Commercialize RNAi Therapeutics Focused On Ocular And Central Nervous System (CNS) Diseases

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, and Regeneron Pharmaceuticals, Inc.

Disrupt or Be Disrupted: Cramer's 'Mad Money' Recap (Wednesday 3/13/19)

Disrupt or Be Disrupted: Cramer's 'Mad Money' Recap (Wednesday 3/13/19)

Disruptors are among the biggest winners, says Jim Cramer. Companies like Apple and Kraft Heinz need to re-imagine their companies in bold, meaningful and even radical ways.

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

In this day and age, companies must be 'disruptors' or get left in the dust.

Teen Scientists Win $1.8 Million At Regeneron Science Talent Search 2019 With Innovative Ideas On Exoplanets, HIV And A Classic Math Problem

Teen Scientists Win $1.8 Million At Regeneron Science Talent Search 2019 With Innovative Ideas On Exoplanets, HIV And A Classic Math Problem

Top Award of $250,000 Goes to Ana Humphrey of Virginia in Nation's Oldest and Most Prestigious STEM Competition for High School Seniors

FDA Approves Dupixent® (dupilumab) For Moderate-to-severe Atopic Dermatitis In Adolescents

FDA Approves Dupixent® (dupilumab) For Moderate-to-severe Atopic Dermatitis In Adolescents

Only therapy that targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis

FDA Approves Dupixent® (dupilumab) For Moderate-to-severe Atopic Dermatitis In Adolescents

FDA Approves Dupixent® (dupilumab) For Moderate-to-severe Atopic Dermatitis In Adolescents

* Only therapy that targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis

TheStreet Quant Rating: B- (Buy)